# US 2016/0256434 A1 · Use of sting agonists to treat hepatitis b virus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256434 A1
- Document ID: US20160256434A1
- Status: Published application
- Kind: A1
- Application number: 15/028,813
- Filed: 2014-10-21
- Published: 2016-09-08
- Earliest claimed: 2013-10-21
- Assignees: Drexel University
- Applicants: Drexel University
- Inventors: JINHONG CHANG; FANG GUO; TIMOTHY M. BLOCK; JU-TAO GUO
- Web page: https://patentgrep.com/patent/US20160256434A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/706: {for hepatitis}
- G01N 33/5067: {Liver cells}
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2333/02: Hepadnaviridae, e.g. hepatitis B virus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention includes methods of treating a subject having hepatitis B viral (HBV) infection. In certain embodiments, the method of the invention comprises stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular STING agonists, thus suppressing HBV replication in hepatocytes. In other embodiments, the method of the invention can be used to treat chronic HBV infections. The invention further provides methods of identifying compounds useful in treating HBV infection in a subject.

## Claims

### Claim 1

A method of treating a subject having a hepatitis B viral (HBV) infection, the method comprising administering a pharmaceutically effective amount of a STING agonist to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the STING agonist stimulates an innate cytokine response in at least one cell selected from the group consisting of macrophages, dendritic cell, liver non-parenchymal cell, and any combinations thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the innate cytokine response is mediated through cytokines.

### Claim 4 (depends on 3)

The method of claim 3, wherein the innate cytokine response is mediated through type 1 interferon.

### Claim 5 (depends on 1)

The method of claim 1, wherein the STING agonist comprises a flavonoid.

### Claim 6 (depends on 5)

The method of claim 5, wherein the flavonoid comprises at least one selected from the group consisting of 10-(carboxymethyl) 9(10H)acridone (CMA), 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), methoxyvone, 6,4′-dimethoxyflavone, 4′-methoxyflavone, 3′,6′-dihydroxyflavone, 7,2′-dihydroxyflavone, daidzein, formononetin, retusin 7-methyl ether, xanthone, and any combinations thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the flavonoid comprises DMXAA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the STING agonist suppresses hepatitis B virus replication in infected hepatocytes.

### Claim 9 (depends on 8)

The method of claim 8, wherein the STING agonist reduces hepatitis B virus capsid levels.

### Claim 10

A method of identifying a compound useful in treating hepatitis B virus (HBV) infection, the method comprising:
treating at least one cell selected from the group consisting of liver resident dendritic cell, macrophage, nonparenchymal cell, and any combination thereof with a test compound, thereby generating a treated cell;
incubating the treated cell in a conditioned medium;
separating the conditioned medium or a portion thereof from the treated cell; and
incubating a HBV-infected hepatocytes with the conditioned medium or portion thereof,
wherein, if the conditioned medium or portion thereof suppresses HBV replication in the HBV-infected hepatocyte, the test compound is identified as a compound useful in treating HBV infection

### Claim 11 (depends on 10)

The method of claim 10, further comprising measuring hepatitis B virus replication in the HBV-infected hepatocyte incubated with the conditioned medium or portion thereof.

### Claim 12 (depends on 10)

The method of claim 10, wherein the treating step stimulates an innate cytokine immune response within the at least one cell, with release of cytokines into the conditioned medium.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cytokines comprises a Type I interferon.

### Claim 14

(canceled)

### Claim 15

A method of treating a subject having a hepatitis B virus (HBV) infection, the method comprising:
treating at least one cell selected from the group consisting of liver resident dendritic cell, macrophage, nonparenchymal cell, and any combinations thereof with a compound, thus generating a treated cell;
incubating the treated cell in a conditioned medium;
separating the conditioned medium or a portion thereof from the treated cell; and
administering the conditioned medium or portion thereof to the subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein the compound comprises at least one STING agonist.

### Claim 17 (depends on 16)

The method of claim 16, wherein the at least one STING agonist comprises a flavonoid.

### Claim 18 (depends on 17)

The method of claim 17, wherein the flavonoid comprises at least one selected from the group consisting of 10-(carboxymethyl) 9(10H)acridone (CMA), 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), methoxyvone, 6,4′-dimethoxyflavone, 4′-methoxyflavone, 3′,6′-dihydroxyflavone, 7,2′-dihydroxyflavone, daidzein, formononetin, retusin 7-methyl ether, xanthone, and any combinations thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the flavonoid comprises DMXAA.

### Claim 20 (depends on 15)

The method of claim 15, wherein the at least one cell is human.

### Claim 21 (depends on 15)

The method of claim 15, wherein the at least one cell is modified to express a mutant STING.

### Claim 22 (depends on 21)

The method of claim 21, wherein at least one cell is transfected or transformed with a mutant STING prior to the treating step.

### Claim 23 (depends on 21)

The method of claim 21, wherein the mutant STING is STING S162A.

### Claim 24 (depends on 15)

The method of claim 15, wherein the at least one cell is autologous to the subject.
